Sickle Cell Disease Drug Market By Drug Type ( Antibiotics, Hydroxyurea, Pain-relieving medications ), By Mode of Administration ( Oral, Intravenous ), By Disease Type ( Sickle cell anemia, Sickle beta thalassemia, Sickle hemoglobin c disease ), By Distribution Channel ( Retail pharmacies, Hospital pharmacies, Online pharmacies ), Industry Trends, Estimation & Forecast, 2017 - 2025

April 2018

 Pages: 184

 ERC 8433

Sickle Cell Disease Drug Market is expected to grow with a CAGR of XX% during the forecast period of 2018 to 2025.

Sickle cell disease refers to a set of inherited diseases that cause the transformation of disc shaped red blood cells into a sickle shaped cells. It is an umbrella term for disease such as sickle cell anemia, sickle hemoglobin C disease, and sickle beta thalassemia. Numerous developments occurring in the industry related to sickle cell disease has led the sickle cell disease drug market to emerge as a lucrative market. Market players are continuously striving to achieve success in developing a permanent drug that can cure the disease. The global sickle cell disease drug market is experiencing hurdles in its growth, owing to the unavailability of drugs in the rural areas of developing nations, malpractices occurring in drug sales, and availability of few FDA approved drugs for sickle cell anemia. In terms of geography, the Middle East and Africa, South America, India are the most lucrative pockets as they are the regions with high prevalence of occurrence of sickle cell disease.

The report provides detailed qualitative and quantitative analysis of the global sickle cell disease drug market. Market size and forecast in terms of value and volume has been provided for the period - (2017 - 2025), for the segments namely drug type, mode of administration, disease type, and distribution channel in each of the major regions of the world.

Global Sickle Cell Disease Drug Market Player Analysis -

The report presents detailed analysis of major players operating in global sickle cell disease drug market. Few of them include Acceleron Pharma, Epidestiny, Errant Gene Therapeutics, Gamida Cell, Pfizer Inc., Global Blood Therapeutics, Hillhurst Biopharmaceuticals, Novartis, bluebird bio, Inc., and Regenacy Pharmaceuticals. Detailed coverage on these market players with information on their revenue from sickle cell disease drug business, market share, gross margin and their growth strategies have been provided in the report.

Market Segmentation

Global sickle cell disease drug market is segmented on the basis of drug type, mode of administration, disease type, distribution channel and geography. On the basis of drug type, the market is categorized into antibiotics, hydroxyurea, pain-relieving medications, and others. By mode of administration, the market is segmented into oral and intravenous. According to disease type, the market is segregated into sickle cell anemia, sickle beta thalassemia, and sickle hemoglobin c disease. Based on distribution channel, the market is segmented into retail pharmacies, hospital pharmacies, and online pharmacies. Geographical coverage has been provided for each of the major regions including North America, Europe, Asia-Pacific, South America and Rest of the World.

Sickle Cell Disease Drug Market Segmentation

By Drug type
   • Antibiotics
   • Hydroxyurea
   • Pain-relieving medications
   • Others

By Mode of administration
   • Oral
   • Intravenous

By Disease type
   • Sickle cell anemia
   • Sickle beta thalassemia
   • Sickle hemoglobin c disease

By Distribution Channel
   • Retail pharmacies
   • Hospital pharmacies
   • Online pharmacies

By Geography
   • North America
            o U.S.
            o Canada
            o Mexico
   • Europe
            o U.K
            o France
            o Germany
            o Italy
            o Spain
            o Rest of Europe
   • Asia-Pacific
            o China
            o Japan
            o India
            o Korea
            o Rest of APAC
   • South America
            o Brazil
            o Rest of South America
   • Rest of the World
            o Middle East
            o Africa

Sickle Cell Disease Drug Market Key Players

• Acceleron Pharma
• Epidestiny
• Errant Gene Therapeutics
• Gamida Cell
• Pfizer Inc.
• Global Blood Therapeutics
• Hillhurst Biopharmaceuticals
• Novartis
• bluebird bio, Inc.
• Regenacy Pharmaceuticals

Please fill in the form below to Request for Customized Report
  
Your personal details are safe and secured with us. Privacy Policy

To request sample copy of this report, please complete the form below verified and secure

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report. This also includes a 30 minute free analyst discussion post report purchase.

  
Your personal details are safe and secured with us. Privacy Policy

    What Information does this report contain?

    • What was the market size of the Sickle Cell Disease Drug Market in 2017 and the expected market size by 2025, along with the growth rate?
    • An in-depth analysis of the current impacting factors, opportunities and challenges/restraints in the market
    • Which are the largest revenue generating products, services or regions and their comparative growth rate?
    • Which technology is in trend and how would it evolve during the forecast period (2017 - 2025)?
    • Which are the leading companies in the Sickle Cell Disease Drug Market and their competitive positioning basis their market share, product portfolio, strategic attempts and business focus?


Purchase Options





Offers & Discounts

  • Chapter purchase
  • Historical market data
  • Country level data breakdown
  • Free customization*
  • Discounts for first time
  • Special pricing for
              non-business entities

Customize

  • We offer 20% free customization on every purchase.

Get in touch!

  +91-844-601-6060


  help@esticastresearch.com